Ephedrine is used to treat low blood pressure and to relieve symptoms of asthma and congestion by opening airways and improving breathing. It can also help with nasal congestion and wheezing.[2] Ephedrine Sulfate is currently approved and in use across 20 indications[4].[1]
Ephedrine Sulfate is one of 381 small molecule programs targeting Cardiovascular Disease. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Patents
Pipeline
Competition
1050 competitors in Asthma
Ephedrine Sulfate
Veramyst
Xolair
Singulair
Nucala
Cinqair
Dupixent
Asmanex
Celexa
Spiriva
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Jan 27, 2017
CORPHEDRA
NDA NDA208943
Mar 1, 2017
EPHEDRINE SULFATE
NDA NDA208609
Jun 14, 2021
REZIPRES
NDA NDA213536
Aug 2, 2021
AKOVAZ
NDA NDA208289
Apr 22, 2022
EPHEDRINE SULFATE
NDA NDA213994
Feb 28, 2023
EMERPHED
NDA NDA213407
Sources
Details